Marshall Wace
NYMX

Marshall Wace’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Marshall Wace’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27,000
Closed -$72K – 826
2016
Q4 		$72K Buy
+27,000
New +$83.7K ﹤0.01% 945

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Marshall Wace's NYMX Position: Q1 2017 in Review

Marshall Wace sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2017, closing a stake of 27,000 shares — an estimated $72K sold.

Marshall Wace first reported a position in NYMX in Q4 2016 and held it in 1 quarter. The position peaked at $72K in Q4 2016. 29 funds tracked by Wall St. Rank hold NYMX as of Q1 2017.

  • Marshall Wace reported no remaining Nymox Pharmaceutical Corp position as of Q1 2017 after selling out during the quarter.
  • Marshall Wace sold 27,000 Nymox Pharmaceutical Corp shares in Q1 2017, an estimated $72K.
  • Marshall Wace first reported a position in Nymox Pharmaceutical Corp in Q4 2016 and held it in 1 quarter.
  • Marshall Wace's Nymox Pharmaceutical Corp position peaked at $72K in Q4 2016.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2017.

Based on Marshall Wace's 13F filing for Q1 2017, filed 12 May 2017.